Log in

OTCMKTS:CBISCannabis Science Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.0050
0.00 (0.00 %)
(As of 11/27/2019)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.06
VolumeN/A
Average Volume4.85 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.
Read More
Cannabis Science logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:CBIS
CUSIP137648101
Phone+1-888-8890888

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CBIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIS and its competitors with MarketBeat's FREE daily newsletter.

Cannabis Science (OTCMKTS:CBIS) Frequently Asked Questions

How were Cannabis Science's earnings last quarter?

Cannabis Science Inc (OTCMKTS:CBIS) issued its earnings results on Tuesday, July, 28th. The company reported $0.00 earnings per share (EPS) for the quarter. View Cannabis Science's earnings history.

Has Cannabis Science been receiving favorable news coverage?

News coverage about CBIS stock has trended negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cannabis Science earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the next several days. View the latest news about Cannabis Science.

Who are some of Cannabis Science's key competitors?

What other stocks do shareholders of Cannabis Science own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cannabis Science investors own include Medical Marijuana (MJNA), Canopy Growth (CGC), Terra Tech (TRTC), 22nd Century Group (XXII), Hemp (HEMP), Aurora Cannabis (ACBFF), Cronos Group (CRON), Aurora Cannabis (ACB), KushCo (KSHB) and Energous (WATT).

Who are Cannabis Science's key executives?

Cannabis Science's management team includes the following people:
  • Mr. Raymond C. Dabney, Co-Founder, Chairman, CEO & Pres (Age 54)
  • Mr. Benjamin C. K. Tam, CFO, Sec. & Director (Age 67)
  • Mr. Robert James Kane, COO & Director (Age 43)
  • Mr. Mario Lap, Pres of European Operations & Director (Age 67)
  • Mr. Bret Bogue, Director of Horticulture and Head of R&D

What is Cannabis Science's stock symbol?

Cannabis Science trades on the OTCMKTS under the ticker symbol "CBIS."

What is Cannabis Science's stock price today?

One share of CBIS stock can currently be purchased for approximately $0.01.

What is Cannabis Science's official website?

The official website for Cannabis Science is www.cannabisscience.com.

How can I contact Cannabis Science?

Cannabis Science's mailing address is 19800 Macarthur Blvd Ste 300, IRVINE, CA 92612-2479, United States. The company can be reached via phone at +1-888-8890888.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.